Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MK-801 limits neurovascular dysfunction during experimental allergic encephalomyelitis

C Bolton1, C Paul

  • 1Pharmacology Group, School of Pharmacy & Pharmacology, University of Bath, United Kingdom.

The Journal of Pharmacology and Experimental Therapeutics
|July 1, 1997
PubMed
Summary

The N-methyl-D-aspartate receptor antagonist MK-801 reduced blood-brain barrier leakage and disease severity in experimental allergic encephalomyelitis, a model for multiple sclerosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Notch Coordinates Periodontal Ligament Maturation through Regulating Lamin A.

Journal of dental research·2019
Same author

Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.

The British journal of dermatology·2012
Same author

A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis.

The British journal of dermatology·2012
Same author

Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis.

ISRN neurology·2012
Same author

Psoriasis: rationale for targeting interleukin-17.

The British journal of dermatology·2012
Same author

Money as motivation to quit: a survey of a non-random Australian sample of socially disadvantaged smokers' views of the acceptability of cash incentives.

Preventive medicine·2012

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Increased blood-brain barrier (BBB) permeability is a hallmark of multiple sclerosis (MS) and its animal model, experimental allergic encephalomyelitis (EAE).
  • Neurovascular damage in cerebral trauma involves N-methyl-D-aspartate (NMDA) receptor activation, treatable with antagonists like MK-801.

Purpose of the Study:

  • To investigate the efficacy of MK-801 in mitigating BBB leakage and disease progression in EAE.
  • To explore the role of NMDA receptor-dependent mechanisms in demyelinating diseases.

Main Methods:

  • Prophylactic and therapeutic administration of MK-801 at varying doses (0.15-0.60 mg/kg) in EAE models.
  • Assessment of BBB integrity using a dual radioisotope technique.
  • Evaluation of neurological deficits and perivascular lesion formation.

Related Experiment Videos

Main Results:

  • Prophylactic MK-801 (0.15 mg/kg) suppressed neurovascular breakdown and neurological deficits.
  • Higher doses of MK-801 (0.30 mg/kg and above) completely prevented BBB extravasation in the cerebellum and inhibited disruption in other brain regions.
  • Both prophylactic and therapeutic MK-801 restricted EAE disease development and lesion formation, though therapeutic use did not further improve BBB suppression when doses were increased.
  • Therapeutic MK-801 counteracted neuroendothelial leakage but did not inhibit inflammatory cell invasion.

Conclusions:

  • MK-801 effectively controls key features of EAE, including BBB disruption and disease progression.
  • These findings strongly implicate NMDA receptor-dependent pathways in the pathogenesis of EAE.
  • The results suggest a potential therapeutic role for NMDA receptor antagonists in human demyelinating conditions like MS.